{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:59:58Z","timestamp":1783702798525,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,7,21]],"date-time":"2012-07-21T00:00:00Z","timestamp":1342828800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s10072-012-1156-0","type":"journal-article","created":{"date-parts":[[2012,7,20]],"date-time":"2012-07-20T21:58:27Z","timestamp":1342821507000},"page":"137-141","source":"Crossref","is-referenced-by-count":42,"title":["Rifampicin and Parkinson\u2019s disease"],"prefix":"10.1007","volume":"34","author":[{"given":"Wei","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuna","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanran","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enxiang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,21]]},"reference":[{"issue":"4\u20135","key":"1156_CR1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0161-813X(02)00098-0","volume":"23","author":"JW Langston","year":"2002","unstructured":"Langston JW (2002) Parkinson\u2019s disease: current and future challenges. Neurotoxicology 23(4\u20135):443\u2013450","journal-title":"Neurotoxicology"},{"issue":"9","key":"1156_CR2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.12968\/bjon.2011.20.9.548","volume":"20","author":"D Heisters","year":"2011","unstructured":"Heisters D (2011) Parkinson\u2019s: symptoms, treatments and research. Br J Nurs 20(9):548\u2013554","journal-title":"Br J Nurs"},{"issue":"3","key":"1156_CR3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/archneur.62.3.353","volume":"62","author":"JL Eriksen","year":"2005","unstructured":"Eriksen JL, Wszolek Z, Petrucelli L (2005) Molecular pathogenesis of Parkinson disease. Arch Neurol 62(3):353\u2013357","journal-title":"Arch Neurol"},{"issue":"4","key":"1156_CR4","first-page":"1275","volume":"32","author":"T Babi","year":"2008","unstructured":"Babi T, Mahovi D (2008) Parkinson\u2019s disease-challenges in new drug development. Coll Antropol 32(4):1275\u20131281","journal-title":"Coll Antropol"},{"issue":"Suppl 1","key":"1156_CR5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s10654-011-9581-6","volume":"26","author":"K Wirdefeldt","year":"2011","unstructured":"Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiology of Parkinson\u2019s disease: a review of the evidence. Eur J Epidemiol 26(Suppl 1):S1\u2013S58","journal-title":"Eur J Epidemiol"},{"issue":"Suppl 17","key":"1156_CR6","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1002\/mds.21675","volume":"22","author":"CW Olanow","year":"2007","unstructured":"Olanow CW (2007) The pathogenesis of cell death in Parkinson\u2019s disease-2007. Mov Disord 22(Suppl 17):S335\u2013S342","journal-title":"Mov Disord"},{"issue":"5","key":"1156_CR7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","volume":"10","author":"WG Meissner","year":"2011","unstructured":"Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E (2011) Priorities in Parkinson\u2019s disease research. Nat Rev Drug Discov 10(5):377\u2013393","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1156_CR8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.brainres.2003.10.012","volume":"996","author":"B Yulug","year":"2004","unstructured":"Yulug B, Kilic U, Kilic E, B\u00e4hr M (2004) Rifampicin attenuates brain damage in focal ischemia. Brain Res 996(1):76\u201380","journal-title":"Brain Res"},{"issue":"8825","key":"1156_CR9","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/0140-6736(92)92870-L","volume":"340","author":"Y Namba","year":"1992","unstructured":"Namba Y, Kawatsu K, Izumi S, Ueki A, Ikeda K (1992) Neurofibrillary tangles and senile plaques in brain of elderly leprosy patients. Lancet 340(8825):978","journal-title":"Lancet"},{"issue":"4","key":"1156_CR10","first-page":"771","volume":"145","author":"DH Chui","year":"1994","unstructured":"Chui DH, Tabira T, Izumi S, Koya G, Ogata J (1994) Decreased beta-amyloid and increased abnormal tau deposition in the brain of aged patients with leprosy. Am J Pathol 145(4):771\u2013775","journal-title":"Am J Pathol"},{"issue":"Pt3","key":"1156_CR11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1042\/bj3220859","volume":"322","author":"T Tomiyama","year":"1997","unstructured":"Tomiyama T, Kaneko H, Kataoka K, Asano S, Endo N (1997) Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem J 322(Pt3):859\u2013865","journal-title":"Biochem J"},{"issue":"12","key":"1156_CR12","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1074\/jbc.271.12.6839","volume":"271","author":"T Tomiyama","year":"1996","unstructured":"Tomiyama T, Shoji A, Kataoka K, Suwa Y, Asano S, Kaneko H, Endo N (1996) Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J Biol Chem 271(12):6839\u20136844","journal-title":"J Biol Chem"},{"issue":"1","key":"1156_CR13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/bbrc.1994.2428","volume":"204","author":"T Tomiyama","year":"1994","unstructured":"Tomiyama T, Asano S, Suwa Y, Morita T, Kataoka K, Mori H, Endo N (1994) Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro. Biochem Biophys Res Commun 204(1):76\u201383","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"1156_CR14","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.chembiol.2004.11.003","volume":"11","author":"A Kapurniotu","year":"2004","unstructured":"Kapurniotu A (2004) Targeting alpha-synuclein in Parkinson\u2019s disease. Chem Biol 11(11):1476\u20131478","journal-title":"Chem Biol"},{"issue":"2","key":"1156_CR15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1359-6446(04)03340-9","volume":"10","author":"J Bradbury","year":"2005","unstructured":"Bradbury J (2005) New hope for mechanism-based treatment of Parkinson\u2019s disease. Drug Discov Today 10(2):80\u201381","journal-title":"Drug Discov Today"},{"issue":"1","key":"1156_CR16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00401-004-0867-6","volume":"108","author":"U Kilic","year":"2004","unstructured":"Kilic U, Kilic E, Lingor P, Yulug B, B\u00e4hr M (2004) Rifampicin inhibits neurodegeneration in the optic nerve transection model in vivo and after 1-methyl-4-phenylpyridinium intoxication in vitro. Acta Neuropathol 108(1):65\u201368","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1156_CR17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.brainres.2006.01.116","volume":"1082","author":"Y Oida","year":"2006","unstructured":"Oida Y, Kitaichi K, Nakayama H, Ito Y, Fujimoto Y, Shimazawa M, Nagai H, Hara H (2006) Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain. Brain Res. 1082(1):196\u2013204","journal-title":"Brain Res."},{"key":"1156_CR18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00005072-199603000-00001","volume":"55","author":"LS Forno","year":"1996","unstructured":"Forno LS (1996) Neuropathology of Parkinson\u2019s disease. J Neuropathol Exp Neurol 55:259\u2013272","journal-title":"J Neuropathol Exp Neurol"},{"key":"1156_CR19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/0929866043407138","volume":"11","author":"FL Martin","year":"2004","unstructured":"Martin FL, Williamson SJ, Paleologou KE, Allsop D, El-Agnaf OM (2004) Alpha-synuclein and the pathogenesis of Parkinson\u2019s disease. Protein Pept Lett 11:229\u2013237","journal-title":"Protein Pept Lett"},{"key":"1156_CR20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2004.10.010","volume":"105","author":"MC Bennett","year":"2005","unstructured":"Bennett MC (2005) The role of alpha-synuclein in neurodegenerative diseases. Pharmacol Ther 105:311\u2013331","journal-title":"Pharmacol Ther"},{"issue":"5","key":"1156_CR21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/138920309789351921","volume":"10","author":"VN Uversky","year":"2009","unstructured":"Uversky VN, Eliezer D (2009) Biophysics of Parkinson\u2019s disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci 10(5):483\u2013499","journal-title":"Curr Protein Pept Sci"},{"key":"1156_CR22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.brainres.2006.12.074","volume":"1139","author":"J Xu","year":"2007","unstructured":"Xu J, Wei C, Xu C, Bennett MC, Zhang G, Li F, Tao E (2007) Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an \u03b1-synuclein multimer. Brain Res 1139:220\u2013225","journal-title":"Brain Res"},{"key":"1156_CR23","first-page":"337","volume":"3","author":"SJ Lee","year":"2003","unstructured":"Lee SJ (2003) alpha-Synuclein aggregation: a link between mitochondrial defects and Parkinson\u2019s disease? Antioxid Redox Signal 3:337\u2013348","journal-title":"Antioxid Redox Signal"},{"issue":"30","key":"1156_CR24","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.2174\/138161208786404191","volume":"14","author":"K Ono","year":"2008","unstructured":"Ono K, Hirohata M, Yamada M (2008) Alpha-synuclein assembly as a therapeutic target of Parkinson\u2019s disease and related disorders. Curr Pharm Des 14(30):3247\u20133266","journal-title":"Curr Pharm Des"},{"key":"1156_CR25","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.chembiol.2004.08.025","volume":"11","author":"J Li","year":"2004","unstructured":"Li J, Zhu M, Rajamani S, Uversky VN, Fink AL (2004) Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol 11:1513\u20131521","journal-title":"Chem Biol"},{"issue":"Suppl 2","key":"1156_CR26","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S1353-8020(03)00023-3","volume":"9","author":"JT Greenamyre","year":"2003","unstructured":"Greenamyre JT, Betarbet R, Sherer TB (2003) The rotenone model of Parkinson\u2019s disease: genes, environment and mitochondria. Parkinsonism Relat Disord 9(Suppl 2):S59\u2013S64","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1156_CR27","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.molbrainres.2004.11.007","volume":"134","author":"CM Testa","year":"2005","unstructured":"Testa CM, Sherer TB, Greenamyre JT (2005) Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res 134(1):220\u2013225","journal-title":"Brain Res Mol Brain Res"},{"key":"1156_CR28","first-page":"RA17","volume":"11","author":"Y Watanabe","year":"2005","unstructured":"Watanabe Y, Himeda T, Araki T (2005) Mechanisms of MPTP toxicity and their implications for therapy of Parkinson\u2019s disease. Med Sci Monit 11:RA17\u2013RA23","journal-title":"Med Sci Monit"},{"key":"1156_CR29","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1523\/JNEUROSCI.22-16-07006.2002","volume":"22","author":"TB Sherer","year":"2002","unstructured":"Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT (2002) An in vitro model of Parkinson\u2019s disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 22:7006\u20137015","journal-title":"J Neurosci"},{"key":"1156_CR30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1196\/annals.1427.015","volume":"1147","author":"AA Starkov","year":"2008","unstructured":"Starkov AA (2008) The role of mitochondria in reactive oxygen species metabolism and signaling. Ann N Y Acad Sci 1147:37\u201352","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"1156_CR31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1023\/B:NERE.0000014827.94562.4b","volume":"29","author":"L Tretter","year":"2004","unstructured":"Tretter L, Sipos I, Adam-Vizi V (2004) Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson\u2019s disease. Neurochem Res 29(3):569\u2013577","journal-title":"Neurochem Res"},{"issue":"Suppl 2","key":"1156_CR32","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.3233\/JAD-2010-100363","volume":"20","author":"J Zhu","year":"2010","unstructured":"Zhu J, Chu CT (2010) Mitochondrial dysfunction in Parkinson\u2019s disease. J Alzheimers Dis 20(Suppl 2):S325\u2013S334","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"1156_CR33","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/187152410793429719","volume":"10","author":"JC Tob\u00f3n-Velasco","year":"2010","unstructured":"Tob\u00f3n-Velasco JC, Carmona-Aparicio L, Ali SF, Santamar\u00eda A (2010) Biomarkers of cell damage induced by oxidative stress in Parkinson\u2019s disease and related models. Cent Nerv Syst Agents Med Chem 10(4):278\u2013286","journal-title":"Cent Nerv Syst Agents Med Chem"},{"issue":"2","key":"1156_CR34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/mi.5.2.7","volume":"5","author":"MW Fariss","year":"2005","unstructured":"Fariss MW, Chan CB, Patel M, Van Houten B, Orrenius S (2005) Role of mitochondria in toxic oxidative stress. Mol Interv 5(2):94\u2013111","journal-title":"Mol Interv"},{"issue":"2","key":"1156_CR35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ana.410310202","volume":"31","author":"MF Beal","year":"1992","unstructured":"Beal MF (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 31(2):119\u2013130","journal-title":"Ann Neurol"},{"issue":"7","key":"1156_CR36","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2174\/0929867013372995","volume":"8","author":"JD Adams Jr","year":"2001","unstructured":"Adams JD Jr, Chang ML, Klaidman L (2001) Parkinson\u2019s disease\u2014redox mechanisms. Curr Med Chem 8(7):809\u2013814","journal-title":"Curr Med Chem"},{"issue":"6","key":"1156_CR37","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1086\/315518","volume":"181","author":"T B\u00f6ttcher","year":"2000","unstructured":"B\u00f6ttcher T, Gerber J, Wellmer A, Smirnov AV, Fakhrjanali F, Mix E, Pilz J, Zettl UK, Nau R (2000) Rifampin reduces production of reactive oxygen species of cerebrospinal fluid phagocytes and hippocampal neuronal apoptosis in experimental Streptococcus pneumoniae meningitis. J Infect Dis 181(6):2095\u20132098","journal-title":"J Infect Dis"},{"issue":"4","key":"1156_CR38","first-page":"251","volume":"5","author":"S Chen","year":"2010","unstructured":"Chen S, Sun Y, Zeng Z, Tao E (2010) Rifampicin inhibits apoptosis in rotenone-induced differentiated PC12 cells by ameliorating mitochondrial oxidative stress. Neural Regen Res 5(4):251\u2013256","journal-title":"Neural Regen Res"},{"issue":"8","key":"1156_CR39","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00702-010-0428-1","volume":"117","author":"L Qian","year":"2010","unstructured":"Qian L, Flood PM, Hong JS (2010) Neuroinflammation is a key player in Parkinson\u2019s disease and a prime target for therapy. J Neural Transm 117(8):971\u2013979","journal-title":"J Neural Transm"},{"issue":"2","key":"1156_CR40","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/187152710791012035","volume":"9","author":"L Lu","year":"2010","unstructured":"Lu L, Li F, Wang X (2010) Novel anti-inflammatory and neuroprotective agents for Parkinson\u2019s disease. CNS Neurol Disord Drug Targets 9(2):232\u2013240","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1156_CR41","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/374647a0","volume":"373","author":"L Meda","year":"1995","unstructured":"Meda L, Cassatella MA, Szendrei GI, Otvos L Jr, Baron P, Villalba M (1995) Activation of microglial cells by \u03b2-amyloid protein and interferon-\u03b3. Nature 373:647\u2013650","journal-title":"Nature"},{"key":"1156_CR42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0960-5428(96)00017-4","volume":"6","author":"J Zielasek","year":"1996","unstructured":"Zielasek J, Hartung HP (1996) Molecular mechanisms of microglial activation. Adv Neuroimmunol 6:191\u2013202","journal-title":"Adv Neuroimmunol"},{"key":"1156_CR43","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brainres.2011.04.019","volume":"1395","author":"W Bi","year":"2011","unstructured":"Bi W, Zhu L, Wang C, Liang Y, Liu J, Shi Q, Tao E (2011) Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation. Brain Res 1395:12\u201320","journal-title":"Brain Res"},{"key":"1156_CR44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1128\/IAI.27.1.15-20.1980","volume":"27","author":"A Bellahs\u00e8ne","year":"1980","unstructured":"Bellahs\u00e8ne A, Forsgren A (1980) Effect of rifampin on the immune response in mice. Infect Immun 27:15\u201320","journal-title":"Infect Immun"},{"key":"1156_CR45","first-page":"25","volume":"174","author":"NV Tsiskarishvili","year":"2009","unstructured":"Tsiskarishvili NV, Tsiskarishvili NI (2009) The anti-tubercular drugs in the treatment of psoriasis. Georgian Med News 174:25\u201328","journal-title":"Georgian Med News"},{"key":"1156_CR46","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jpain.2008.01.325","volume":"9","author":"MD Hamid Namazi","year":"2008","unstructured":"Hamid Namazi MD (2008) Practice pearl: a novel use of rifampicin for treatment of carpal tunnel syndrome. J Pain 9:380\u2013381","journal-title":"J Pain"},{"key":"1156_CR47","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nm0198-092","volume":"4","author":"C Calleja","year":"1998","unstructured":"Calleja C, Pascussi JM, Mani JC, Maurel P, Vilarem MJ (1998) The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nat Med 4:92\u201396","journal-title":"Nat Med"},{"key":"1156_CR48","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4196\/kjpp.2009.13.6.475","volume":"13","author":"SK Kim","year":"2009","unstructured":"Kim SK, Kim YM, Yeum CE, Jin SH, Chae GT, Lee SB (2009) Rifampicin Inhibits the LPS-induced Expression of Toll-like Receptor 2 via the Suppression of NF-kappaB DNA-binding Activity in RAW 264.7 Cells. Korean J Physiol Pharmacol 13:475\u2013482","journal-title":"Korean J Physiol Pharmacol"},{"issue":"5","key":"1156_CR49","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1472-8206.2008.00616.x","volume":"22","author":"G Dutta","year":"2008","unstructured":"Dutta G, Zhang P, Liu B (2008) The lipopolysaccharide Parkinson\u2019s disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol 22(5):453\u2013464","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"1156_CR50","doi-asserted-by":"crossref","first-page":"E606","DOI":"10.1208\/aapsj080369","volume":"8","author":"B Liu","year":"2006","unstructured":"Liu B (2006) Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson\u2019s disease. AAPS J 8(3):E606\u2013E621","journal-title":"AAPS J"},{"key":"1156_CR51","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00702-010-0428-1","volume":"117","author":"L Qian","year":"2010","unstructured":"Qian L, Flood PM, Hong JS (2010) Neuroinflammation is a key player in Parkinson\u2019s disease and a prime target for therapy. J Neural Transm 117:971\u2013979","journal-title":"J Neural Transm"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-012-1156-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-012-1156-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-012-1156-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T07:55:43Z","timestamp":1594454143000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-012-1156-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,21]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["1156"],"URL":"https:\/\/doi.org\/10.1007\/s10072-012-1156-0","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,21]]}}}